Stanford Rudnick - 31 Mar 2023 Form 3 Insider Report for Syneos Health, Inc. (SYNH)

Role
Interim Chief Financial Officer Exhibit List: Exhibit 24 - Power of Attorney
Signature
/s/ Sara Epstein, Attorney-in-Fact
Issuer symbol
SYNH
Transactions as of
31 Mar 2023
Transactions value $
$0
Form type
3
Filing time
10 Apr 2023, 17:03:47 UTC
Next filing
19 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SYNH Class A Common Stock 31.5K 31 Mar 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SYNH Stock Option (Right to Buy Class A Common Stock) 31 Mar 2023 Class A Common Stock 166 $43.16 Direct F2
holding SYNH Stock Option (Right to Buy Class A Common Stock) 31 Mar 2023 Class A Common Stock 537 $42.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (i) 408 restricted stock units ("RSUs") that vest on April 18, 2023; (ii) 612 RSUs that vest on April 18, 2023; (iii) 704 RSUs that vest on May 16, 2023; (iv) 704 RSUs that vest on January 15, 2024; (v) 2,345 RSUs that vest on January 17, 2024; (vi) 610 RSUs that vest on January 18, 2024; (vii) 1,407 RSUs that vest on February 15, 2024; (viii) 217 RSUs that vest on February 16, 2024; (ix) 408 RSUs that vest on April 18, 2024; (x) 612 RSUs that vest on April 18, 2024; (xi) 2,112 RSUs that vest on May 16, 2024; (xii) 5,782 RSUs that vest on December 15, 2024; (xiii) 2,345 RSUs that vest on January 17, 2025; (xiv) 611 RSUs that vest on January 18, 2025; (xv) 1,407 RSUs that vest on February 15, 2025; (xvi) 408 RSUs that vest on April 18, 2025; (xvii) 612 RSUs that vest on April 18, 2025; (xviii) 2,346 RSUs that vest on January 17, 2026; (xix) 1,408 RSUs that vest on February 15, 2026, all subject to continued employment.
F2 The shares subject to this option are fully vested.

Remarks:

Interim Chief Financial Officer Exhibit List: Exhibit 24 - Power of Attorney